Genmab — Juli 2024
-
Ben Derman
@bdermanmd
Let’s talk about freedom…from spending as much time in clinic!We piloted discontinuation of premeds for daratumumab starting cycle 2 (we kept dex) and had no adverse events! https://x.com/bdermanmd/status/1808701446549807569
-
-
The New England Journal of Medicine - Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2313811
-
Health Canada Authorizes RYBREVANT
(amivantamab) in Combination with Carboplatin and Pemetrexed https://finance.yahoo.com/news/health-canada-authorizes-rybrevant-amivantamab-120000634.html -
PERSEUS Data Support Daratumumab as New Standard of Care for Myeloma https://bloodcancerstoday.com/post/perseus-data-support-daratumumab-as-new-standard-of-care-for-myeloma
-
Iflg Bloomberg overgåes væksten i Gmab de næste 5 år (17,5%) kun af LLY. NVO (17,2%) blandt alle de 15 største pharma/biotech. En vækst historie som markedet tilsyneladende ikke tror på, da den skal drives af Gen1046 og Epco. HexaCD38 fylder ingenting de næste 5år.
-
Forventninger til C25 halvårsregnskaber https://proinvestor.com/boards/121235
-
-
Tisotumab vedotin shows superior survival results in advanced cervical cancer https://www.healio.com/news/hematology-oncology/20240703/tisotumab-vedotin-shows-superior-survival-results-in-advanced-cervical-cancer
-
ADCs: The New Frontier in Cancer Treatment https://www.pharmacytimes.com/view/adcs-the-new-frontier-in-cancer-treatment
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind